Robert Vonderheide
罗伯特·冯德海德
MD, DPhil
Director, Abramson Cancer Center; Professor of MedicineAbramson癌症中心主任；医学教授
👥Biography 个人简介
Robert Vonderheide is a leading authority on pancreatic cancer immunotherapy, most notably for developing CD40 agonist strategies that reprogram the immunosuppressive tumor microenvironment of PDAC.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
CD40 Agonist Immunotherapy
Established CD40 agonists as a strategy to activate macrophages and overcome immune exclusion in pancreatic cancer, advancing multiple clinical trials of CD40-based combinations.
Tumor Microenvironment Reprogramming
Defined mechanisms by which myeloid cells suppress anti-tumor immunity in PDAC, providing rationale for targeting stromal immunosuppression to enhance checkpoint immunotherapy.
Combination Immunotherapy Trials
Led pioneering clinical trials combining CD40 agonists with chemotherapy and PD-1 blockade in pancreatic cancer, demonstrating feasibility and early signals of efficacy.
Representative Works 代表性著作
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma
Science (2011)
Landmark study showing CD40 activation depletes tumor stroma and enables T-cell independent tumor regression in PDAC.
Macrophage-based immunotherapy of pancreatic ductal adenocarcinoma
Cancer Cell (2021)
Demonstrated macrophage reprogramming via CD40 agonism combined with chemotherapy improves outcomes in PDAC models.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Zev Wainberg
UCLA Health / David Geffen School of Medicine
Cathy Eng
Vanderbilt-Ingram Cancer Center
Daniel Coit
Memorial Sloan Kettering Cancer Center
Johanna Bendell
Sarah Cannon Research Institute
关注 罗伯特·冯德海德 的研究动态
Follow Robert Vonderheide's research updates
留下邮箱，当我们发布与 Robert Vonderheide（University of Pennsylvania）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment